July 11, 2016
Concordia International Corp. Script Tracker - Week Ended July 1st
Our view: We continue to highlight Rx trends in our CXRX notes, and subsequently, we believe it is important to provide investors with a more in-depth view of script trends going forward.
Key points:
Plaquenil AG TRx up 2.0% WoW, underperforms broader market. As we have previously noted, the supply chain issues that held plaquenil back in Q4/15 appear to be resolved. Plaquenil AG (Prasco) TRx were up 2.0% WoW vs. down 1.1% the prior week. Total hydroxychloroquine (broader plaquenil market) TRx were up 4.5% WoW and Prasco's market share (Concordia AG) currently sits at 40.8% of TRx vs. 41.8% the prior week. We have outlined Plaquenil/ hydroxychloroquine market share trends in Exhibit 2.
Lanoxin AG TRx up 7.6% WoW. Par's (AG) market share increased from 39.7% to 40.0%, Sun Pharma's market share increased from 14.5% to 14.7%, WestWard Pharma's share remained at 13.4%, and Impax's share decreased from 30.8% to 30.2%. The Lanoxin AG (Par Pharma) saw TRx increase 7.6% WoW vs. a 1.6% decrease last week. The broader market saw TRx increase 6.8% WoW. We have outlined Lanoxin/digoxin market trends in Exhibit 3.
Donnatal TRx down 3.0% WoW as IBS market continues to face competitive headwinds. As previously noted, we have been monitoring the market share of several IBS drugs, both IBS-C and IBS-D drugs, and we anticipate Donnatal scripts have seen slight weakness in the face of Allergan’s Viberzi launch (TRx down 0.3% WoW), which came to market in December 2015. Donnatal NRx were up 1.2% WoW vs. down 1.3% the prior week and TRx were down 3.0% WoW vs. down 2.7% the prior week. Donnatal's current market share (TRx) is 1.8%; Xifaxan holds a 16.4% market share, Viberzi has a 3.2% share, Amitiza has a 28.0% share, and Linzess has a 50.3% share. Viberzi and Linzess, both Allergan products, have seen a gain in share since the December launch, as outlined in Exhibit 4. Exhibit 5 shows Donnatal weekly NRx and TRx trends. We continue to believe that IMS does not capture all channels of the IBS market, accounting for the difference relative to CXRX commentary.
Other CXRX products - Nilandron TRx up 20.0% WoW, Dibenzyline AG TRx up 3.7% WoW, and Kapvay up 3.1% WoW. Nilandron, which has seen recent investment in its salesforce, saw TRx up 20.0% WoW to 60 scripts vs. down 10.7% the prior week. Concordia's dibenzyline AG (Prasco) saw TRx up 3.7% WoW to 28 scripts vs. up 3.8% the prior week. We note that the low Nilandron and Dibenzyline script counts lead to volatility in weekly trends.